Show simple item record

dc.contributor.authorZarzuelo Romero, María José 
dc.contributor.authorPérez Ramírez, Cristina 
dc.contributor.authorCura, Yasmín
dc.contributor.authorCarrasco Campos, María Isabel
dc.contributor.authorMarangoni Iglecias, Luciana María
dc.contributor.authorRamírez Tortosa, María Carmen 
dc.contributor.authorJiménez Morales, Alberto
dc.date.accessioned2021-11-23T11:50:55Z
dc.date.available2021-11-23T11:50:55Z
dc.date.issued2021-10-15
dc.identifier.citationZarzuelo-Romero, M.J... [et al.]. Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients. J. Pers. Med. 2021, 11, 1032. [https://doi.org/10.3390/jpm11101032]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/71693
dc.description.abstractMultiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of autoimmune origin, in which inflammation and demyelination lead to neurodegeneration and progressive disability. Treatment is aimed at slowing down the course of the disease and mitigating its symptoms. One of the first-line treatments used in patients with MS is glatiramer acetate (GA). However, in clinical practice, a response rate of between 30% and 55% is observed. This variability in the effectiveness of the medication may be influenced by genetic factors such as polymorphisms in the genes involved in the pathogenesis of MS. Therefore, this review assesses the impact of genetic variants on the response to GA therapy in patients diagnosed with MS. The results suggest that a relationship exists between the effectiveness of the treatment with GA and the presence of polymorphisms in the following genes: CD86, CLEC16A, CTSS, EOMES, MBP, FAS, TRBC1, IL1R1, IL12RB2, IL22RA2, PTPRT, PVT1, ALOX5AP, MAGI2, ZAK, RFPL3, UVRAG, SLC1A4, and HLA-DRB1*1501. Consequently, the identification of polymorphisms in these genes can be used in the future as a predictive marker of the response to GA treatment in patients diagnosed with MS. Nevertheless, there is a lack of evidence for this and more validation studies need to be conducted to apply this information to clinical practice.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMultiple esclerosises_ES
dc.subjectGlatiramer acetatees_ES
dc.subjectMyelin basic proteines_ES
dc.subjectResponsees_ES
dc.subjectTreatment es_ES
dc.subjectPolymorphismses_ES
dc.subjectPharmacogeneticses_ES
dc.subjectMedicine personalizedes_ES
dc.titleInfluence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/jpm11101032
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España